Sethi S, Fervenza FC (2011) Membranoproliferative glomerulonephritis: pathogenetic heterogeneity and proposal for a new classification. SeminNephrol 31:341–348

CAS  Google Scholar 

D’Agati VD, Bomback AS (2012) C3 glomerulopathy: What’s in a name? Kidney Int 82:379–381

Article  PubMed  Google Scholar 

Cook HT, Pickering MC (2018) Clusters not classifications: making sense of complement-mediated kidney injury. J Am SocNephrol 29(1):9–12

CAS  Google Scholar 

Fervenza FC, Sethi S, Glassock RJ (2012) Idiopathic membranoproliferative glomerulonephritis: does it exist? Nephrol Dial Transplant 27(12):4288–4294

Article  CAS  PubMed  Google Scholar 

Chothia MY, Panday SA, Coetzee L, Bates W et al (2020) Outcomes of immunoglobulin-associated mesangiocapillary glomerulonephritis: a South African experience. Nephrology 25(10):765–774

Article  CAS  PubMed  Google Scholar 

Orth SR, Ritz E (1998) The nephrotic syndrome. N Engl J Med 338:1202–1211

Article  CAS  PubMed  Google Scholar 

Schmitt H, Bohle A, Reineke T, Mayer-Eichberger D, Vogl W Long term prognosis of membranoproliferative glomerulonephritis type I. Significance of clinical and morphological parameters: an investigation of 220 cases. Nephron 1990; 55: 242–250.

Farvenza FC, Sethi S, Glassock RJ, Waltham, MA. Membranoproliferative glomerulonephritis: Classification, clinical features, and diagnosis. UpToDate; 2022 [cited 2024 June 05].http://www.uptodate.com.

Levey AS, Stevens LA, Schmid CH et al (2009) A new Equation to estimate glomerular filtration rate. Ann Intern Med 150:604–612

Article  PubMed  PubMed Central  Google Scholar 

Renal Disease Subcommittee of the American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria The American college of rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. Arthritis Rheum 2006; 54: 421–432.

Okuda Y, Ishikura K, Hamada R, Harada R, Sakai T, Hamasaki Y et al (2015) Membranoproliferative glomerulonephritis and C3 glomerulonephritis: frequency, clinical features, and outcome in children. Nephrology (Carlton) 20:286–292

Article  CAS  PubMed  Google Scholar 

Kawasaki Y, Kanno S, Ono A, Suzuki Y, Ohara S, Sato M et al (2016) Differences in clinical findings, pathology, and outcomes between C3 glomerulonephritis and membranoproliferative glomerulonephritis. Pediatr Nephrol 31:1091–1099

Article  PubMed  Google Scholar 

Holle J, Berenberg-Gossler L, Wu K, Beringer O, Kropp F, Muller D et al (2018) Outcome of membranoproliferative glomerulonephritis and C3-glomerulopathy in children and adolescents. Pediatr Nephrol 33:2289–2298

Article  PubMed  Google Scholar 

Khandelwal P, Bhardwaj S, Singh G, Sinha A, Hari P (2021) Bagga A Therapy and outcomes of C3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis. Pediatr Nephrol 36:591–600

Article  PubMed  Google Scholar 

Kirpalani A, Jawa N, Smoyer WE, Licht C (2020) Midwest Pediatric Nephrology CLong-Term Outcomes of C3 Glomerulopathy and Immune-Complex Membranoproliferative Glomerulonephritis in Children. Kidney Int Rep 5:2313–2324

Article  PubMed  PubMed Central  Google Scholar 

Nakano M, Karasawa K, Moriyama T, Uchida K (2019) Nitta K Characteristics of membranoproliferative glomerulonephritis based on a new classification at a single center. Clin Exp Nephrol 23:852–858

Article  PubMed  Google Scholar 

Nargund P, Kambham N, Mehta K, Lafayette RA (2015) Clinicopathological features of membranoproliferative glomerulonephritis under a new classification. Clin Nephrol 84:323–330

Article  PubMed  Google Scholar 

Nakagawa N, Mizuno M, Kato S, Maruyama S, Sato H, Nakaya I et al (2021) Demographic, clinical characteristics and treatment outcomes of immune-complex membranoproliferative glomerulonephritis and C3 glomerulonephritis in Japan: a retrospective analysis of data from the Japan Renal Biopsy Registry. PLoS ONE 16(9):e0257397

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fakhouri F, Le Quintrec M (2020) Fremeaux-Bacchi V Practical management of C3 glomerulopathy and Ig-mediated MPGN: facts and uncertainties. Kidney Int 98:1135–1148

Article  CAS  PubMed  Google Scholar 

Iatropoulos P, Noris M, Mele C, Piras R, Valoti E, Bresin E et al (2016) Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome. Mol Immunol 71:131–142

Article  CAS  PubMed  Google Scholar 

Schmitt H, Bohle A, Reineke T, Mayer-Eichberger D, Vogl W (1990) Long-term prognosis of membranoproliferative glomerulonephritis type I. Nephron 55:242–250

Article  CAS  PubMed  Google Scholar 

Chan M, Chan K, Chan P, Fang G, Cheng I (1989) Adult-onset mesangiocapillary glomerulonephritis: a disease with a poor prognosis. QJM 72:599–607

CAS  PubMed  Google Scholar 

Nakagawa N, Hasebe N, Hattori M, Nagata M, Yokoyama H, Sato H et al (2018) Clinical features and pathogenesis of membranoproliferative glomerulonephritis: a nationwide analysis of the Japan renal biopsy registry from 2007 to 2015. Clin Exp Nephrol 22:797–807

Article  PubMed  Google Scholar 

Cameron JS, Turner DR, Heaton J, Williams DG, Ogg CS, et al. Idiopathic mesangiocapillary glomerulonephritis. Comparison of types I and II in children and adults and long-term prognosis. Am J Med. 1983; 74: 175–192.

Bomback AS, Santoriello D, Avasare RS, Regunathan-Shenk R, Canetta PA, Ahn W et al (2018) C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy. Kidney Int 93:977–985

Article  PubMed  Google Scholar 

Puri P, Walters GD, Fadia MN, Konia M, Gibson KA, Jiang SH.Puri P, et al. The impact of reclassification of C3 predominant glomerulopathies on diagnostic accuracy, outcome and prognosis in patients with C3glomerulonephritis. BMC Nephrol. 2020;21(1):265.

Faedda R, Satta A, Tanda F, Pirisi M, Bartoli E (1994) Immunosuppressive treatment of membranoproliferative glomerulonephritis. Nephron 67(1):59–65

Article  CAS  PubMed  Google Scholar 

Braun MC, West CD, Strife CF (1999) Differences between membranoproliferativeglomerulonephritis types I and III in long-term response to an alternate-day prednisone regimen. Am J Kidney Dis 34(6):1022–1032

Article  CAS  PubMed  Google Scholar 

Avasare RS, Canetta PA, Bomback AS, Marasa M, Caliskan Y, Ozluk Y et al (2018) Mycophenolate mofetil in combination with steroids for treatment of C3 glomerulopathy: a case series. Clin J Am Soc Nephrol 13(3):406–413

Article  CAS  PubMed  PubMed Central  Google Scholar 

Caliskan Y, Torun ES, Tiryaki TO, Oruc A, Ozluk Y, Akgul SU et al (2017) Immunosuppressive treatment in C3 glomerulopathy: Is it really effective? Am J Nephrol 46(2):96–107

Article  CAS  PubMed  Google Scholar 

Bomback AS (2014) Eculizumab in the treatment of membranoproliferative glomerulonephritis. Nephron Clin Pract 128:270–276

Article  CAS  PubMed  Google Scholar